Clinical trial phase II (single centre study) : a preliminary study of the safety, immunogenicity, and clinical efficacy of TroVax given in conjunction with interleukin 2 (IL-2) in the treatment of stage IV renal cell cancer

Trial Profile

Clinical trial phase II (single centre study) : a preliminary study of the safety, immunogenicity, and clinical efficacy of TroVax given in conjunction with interleukin 2 (IL-2) in the treatment of stage IV renal cell cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Interleukin-2 (Primary) ; MVA 5T4 (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 10 Nov 2008 New source identified and integrated (Current Controlled Trials record ISRCTN83977250)
    • 31 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2008 Results presented at American Society of Clinical Oncology (ASCO) annual meeting in 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top